AC
DXCM icon

Avestar Capital’s DexCom DXCM Stock Holding History

Avestar Capital’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,951
Closed -$345K – 494
2025
Q2 		$345K Sell
3,951
-730
-16% -$57.2K 0.02% 368
2025
Q1 		$320K Sell
4,681
-1,161
-20% -$94.7K 0.03% 364
2024
Q4 		$454K Buy
5,842
+1,766
+43% +$131K 0.04% 308
2024
Q3 		$273K Buy
4,076
+1,308
+47% +$107K 0.03% 371
2024
Q2 		$314K Sell
2,768
-162
-6% -$20.5K 0.03% 330
2024
Q1 		$406K Buy
2,930
+490
+20% +$61.6K 0.04% 267
2023
Q4 		$303K Buy
+2,440
New +$249K 0.03% 292
2023
Q3 		– Sell
-1,965
Closed -$253K – 374
2023
Q2 		$253K Buy
1,965
+97
+5% +$11.7K 0.04% 264
2023
Q1 		$217K Buy
1,868
+5
+0.3% +$560 0.04% 281
2022
Q4 		$211K Buy
+1,863
New +$205K 0.04% 270
2019
Q3 		– Sell
-80
Closed -$2K – 353
2019
Q2 		$2K Hold
80
– – ﹤0.01% 679
2019
Q1 		$2K Buy
+80
New +$2.81K ﹤0.01% 652

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Avestar Capital's DXCM Position: Q3 2025 in Review

Avestar Capital sold out of DexCom (DXCM) in Q3 2025, closing a stake of 3,951 shares — an estimated $345K sold.

Avestar Capital first reported a position in DXCM in Q1 2019 and held it in 12 quarters. The position peaked at $454K in Q4 2024. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

  • Avestar Capital reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
  • Avestar Capital sold 3,951 DexCom shares in Q3 2025, an estimated $345K.
  • Avestar Capital first reported a position in DexCom in Q1 2019 and held it in 12 quarters.
  • Avestar Capital's DexCom position peaked at $454K in Q4 2024.
  • 911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Avestar Capital's 13F filing for Q3 2025, filed 7 Nov 2025.